Silexion Therapeutics Corp
Research Silexion Therapeutics Corp (SLXN) on Bullrun: market cap USD 430.63K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLXN
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 430.63K
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.73M
- Free cash flow-USD 3.65M
Valuation Snapshot
latest market cap is USD 430.63K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 11.91M | -USD 10.83M | n/a | 8.96 | USD 5.99M | USD 2.04M | USD 2.60M |
| FY2024 | USD 0 | -USD 16.52M | -USD 8.42M | n/a | 394.94 | USD 1.19M | USD 4.49M | -USD 3.99M |
| FY2023 | n/a | -USD 5.11M | -USD 4.54M | n/a | 659.55 | USD 4.60M | USD 171.00K | -USD 15.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 430.63K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.00M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | n/a | 739.8 | n/a | n/a |
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Silexion Therapeutics Corp's market cap?
Silexion Therapeutics Corp's market capitalization is USD 430.63K.
What does Silexion Therapeutics Corp do?
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.